T1	p 43 121	early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy .
T2	p 320 367	Type 2 diabetic patients ( N.=57 ) were divided
T3	p 373 479	two groups as with nephropathy ( N.=27 ) and without nephropathy ( N.=30 ) . Diabetic nephropathy patients
T4	p 841 860	diabetic group with
T5	p 1355 1405	2 diabetes mellitus patients with nephropathy than
T6	p 1414 1425	nephropathy
T7	i 101 119	pyridoxine therapy
T8	i 175 186	AGE-peptide
T9	i 248 311	thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 ) therapy .
T10	i 505 557	B6 ( N.=12 ) ( 250 mg/day ) or B1+B6 ( N.=15 ) ( 250
T11	i 1075 1077	B6
T12	o 175 186	AGE-peptide
T13	o 653 770	glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and
T14	o 984 995	nephropathy
T15	o 1196 1241	increase in C-peptide ( P=0.006 , P=0.004 ) .
T16	o 1285 1304	plasma AGE-peptides
T17	o 1605 1619	in C-peptide .